Receptor subtypes involved in tachykinin-mediated edema formation

Area of Science:

• Pharmacology
• Neuroscience
• Immunology

Background:

• Tachykinins are neuropeptides involved in inflammatory processes.
• Substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) are key members of the tachykinin family.
• The specific roles of NK1, NK2, and NK3 receptor subtypes in mediating tachykinin-induced edema are not fully elucidated.

Purpose of the Study:

• To investigate the involvement of NK1, NK2, and NK3 receptor subtypes in mediating rat paw edema induced by natural tachykinins and their selective agonists.
• To assess the efficacy of selective NK1, NK2, and NK3 receptor antagonists in inhibiting tachykinin-induced edema.

Main Methods:

• Intradermal (ID) injection of tachykinins (SP, NKA, NKB) and their selective agonists (SP methyl-ester, beta-Ala, senktide) into rat paws to induce edema.
• Administration of selective NK1 (FK888), NK2 (SR 48968), and NK3 (SR 142801) receptor antagonists.
• Quantification of rat paw edema volume and calculation of ED50 values for agonists and inhibition percentages for antagonists.

Main Results:

• Natural tachykinins (SP, NKA, NKB) and their selective agonists dose-dependently induced significant rat paw edema.
• Selective NK1, NK2, and NK3 receptor agonists demonstrated potent edematogenic activity with low ED50 values.
• NK1, NK2, and NK3 receptor antagonists effectively inhibited edema formation induced by various tachykinins and agonists, with NK1 antagonists showing particularly strong inhibition.

Conclusions:

• Tachykinin-mediated rat paw edema is dependent on the activation of NK1, NK2, and NK3 receptor subtypes.
• NK1 receptors appear to play a major role in mediating SP-induced edema.
• These findings highlight the therapeutic potential of targeting tachykinin receptors in inflammatory conditions.